Cellectis to Participate in Upcoming Investor Conferences [EN]
Publié le 04 septembre 2017 à New York (N.Y.)
September 4, 2017 – New York (N.Y.) – Cellectis (Alternext: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), will present at several upcoming investor conferences. Three of them will be webcasted live. The replay will be available in the Investor Relations section of the Company’s website at https://www.cellectis.com/en/investors/events-and-webcasts/
September 6, 2017, André Choulika, CEO of Cellectis, to present at the Wells Fargo Conference in Boston from 4:10 to 4:40pm ET
September 11, 2017, André Choulika to present at the Morgan Stanley Global Healthcare Conference in New York from 9:20 to 9:50am ET
September 26, 2017, André Choulika to present at the Ladenburg Thalmann 2017 Conference in New York from 2:00 to 2:25pm ET
September 28, 2017, André Choulika to present at the Leerink Rare Disease & Immuno-Oncology Conference in New York at 2:30 pm ET